YOLFTbeta
Genesystem Co. Ltd.

Genesystem Co. Ltd.

363250 · KQ · Healthcare / Diagnostics & Research

3,940.00KRW+40.00 (+1.03%)

Price History

Full chart

Market Stats

Previous Close3,900.00
Open3,895.00
Day Range3,865.00 – 3,970.00
52-Week Range2,850.00 – 7,260.00
Volume335
Market Cap31.57B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.06
50-Day Avg4,179.60
200-Day Avg4,602.38

About

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits. The company also operates as an electrical components and equipment company. The company was incorporated in 2010 and is based in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • Employees25
  • Headquarters200-9, Techno 2-ro, Daejeon, South Korea, 34028, Korea
  • Websitehttps://www.genesystem.co.kr

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue498.88M1.13B13.26B13.24B3.65B897.03M1.21B381.36M
Growth (%)-+127.48%+1068.27%-0.16%-72.40%-75.44%+34.64%-68.42%
Cost of Revenue387.74M819.35M4.27B4.57B2.49B2.48B3.03B2.85B
Gross Profit111.14M315.52M8.99B8.67B1.17B-1.59B-1.82B-2.46B
Gross Margin22.28%27.80%67.78%65.47%31.96%-176.82%-150.68%-646.35%
Operating Expense1.73B2.81B5.66B6.40B7.77B7.90B8.30B7.22B
Operating Income-1.62B-2.49B3.33B2.27B-6.60B-9.48B-10.12B-9.69B
Operating Margin-324.33%-219.78%25.10%17.12%-180.80%-1057.32%-837.58%-2540.06%
EBITDA-----6.58B-7.23B-8.30B-14.77B
EBITDA Margin-----180.07%-806.40%-687.29%-3872.54%
Net Income-2.48B-4.04B-2.22B3.55B-9.00B-7.92B-8.92B-11.96B
Net Income Margin-496.25%-356.08%-16.77%26.83%-246.26%-882.41%-738.17%-3134.97%
R&D--1.63B2.84B3.35B3.43B3.34B2.69B
R&D as % of Total Revenue--12.30%21.47%91.80%381.84%276.88%705.08%
Interest Expense00445.55M88.86M95.47M133.61M136.25M124.58M
Interest Expense % of Total Revenue0.00%0.00%3.36%0.67%2.61%14.89%11.28%32.67%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.16B2.04B18.92B50.66B41.18B38.93B29.90B14.40B
Total Liabilities13.00B14.73B6.60B6.57B6.07B11.47B10.63B6.65B
Total Equity-8.85B-12.70B12.32B44.09B35.11B27.46B19.27B7.85B
Cash3.21B802.05M9.06B25.63B16.84B9.09B5.62B1.11B
Total Debt3.55B2.34B3.86B-----
Net Debt-------2.63B

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.68B-2.09B3.70B985.71M-6.42B-7.81B-7.34B-6.88B
Investing Cash Flow-166.62M-287.94M-5.76B-12.90B-2.56B-85.42M5.57B-
Financing Cash Flow3.40B-29.22M11.06B27.85B181.32M178.48M-1.72B-
Capital Expenditure169.14M298.11M5.78B323.95M238.43M418.81M361.10M334.28M
Free Cash Flow---2.09B187.47M-6.74B-8.23B-7.70B-7.22B
FCF to OCF---56.41%19.02%105.07%105.36%104.92%104.86%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate--------------------
EPS Actual97.88122.71172.45-86.24-233.74-283.72-699.40-314.93-281.47-328.07-214.52-311.19-290.39-253.37-427.60-261.53-325.59-298.40-868.55-221.86
Surprise--------------------
Timing--------------------

Key Statistics & Ratios

Market Cap31.57B
Enterprise Value33.87B
Trailing P/E0.00
Forward P/E0.00
Price / Sales31.26
Price / Book2.95
Revenue (TTM)1.01B
Gross Profit (TTM)-2.01B
EBITDA-7.28B
Profit Margin0.00%
Operating Margin-221.66%
Return on Equity-86.82%
Return on Assets-22.78%
Shares Outstanding7.57M
Shares Float5.52M
Beta-0.06
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%